
KRRO Stock Forecast & Price Target
KRRO Analyst Ratings
Bulls say
Korro Bio is a promising biopharmaceutical company with a solid plan for developing and commercializing genetic medicines based on RNA editing. Their focus on targeting hyperammonemia, a well-established disease with clear metrics for approval, provides a clear path for success with their lead program KRRO-121. Their recent PIPE financing and strong balance sheet support their continued growth and we expect their stock to perform well in the near future, with our Buy rating and updated 12-month price target of $15 per share.
Bears say
Korro Bio is currently generating no revenue from its products, which is a significant financial concern. Additionally, the company has yet to bring any of its products to market and its clinical trials have been delayed, leading to further uncertainty and potential financial setbacks. The lack of revenue and potential obstacles in the company's pipeline make it a risky investment with a negative outlook on its stock.
This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KRRO Analyst Forecast & Price Prediction
Start investing in KRRO
Order type
Buy in
Order amount
Est. shares
0 shares